Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
Net Profit (TTM)
$0 Mln
ROE
-24.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
8
Industry P/E
--
EV/EBITDA
-4.4
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$0.3
EPS
$-1.2
Face value
--
Shares outstanding
7,215,860
CFO
$--
EBITDA
$--
Net Profit
$--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neuraxis Inc (NRXS)
| -5.5 | 28.3 | -8.1 | -21.3 | -- | -- | -- |
|
BSE Sensex
| 5.5 | 9.8 | 8.7 | 12.9 | 16.1 | 21.5 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
|---|---|
|
Neuraxis Inc (NRXS)
| -11.9 |
|
S&P Small-Cap 600
| 7.0 |
|
BSE Sensex
| 8.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Neuraxis Inc (NRXS)
|
2.2 | 16.6 | 2.7 | -8.2 | -275.0 | -2480.5 | -- | 8.0 |
| 2.2 | 3.5 | 0.6 | -8.0 | -1,245.8 | -178.5 | -- | 0.0 | |
| 0.3 | 4.2 | 7.5 | -9.0 | -144,731.8 | -0.3 | -- | 0.7 | |
| 0.7 | 162.9 | 1.0 | -155.9 | -15,251.5 | -- | -- | 0.0 | |
| 119.1 | 11,854.7 | 5,512.6 | 494.7 | 17.0 | 13.8 | 24.2 | 5.5 | |
| 0.6 | 200.2 | 0.0 | -2.4 | -- | 299.5 | -- | 0.0 | |
| 7.4 | 202.1 | 43.0 | -75.0 | -167.4 | -40.8 | -- | 1.4 | |
| 1.2 | 166.7 | 41.6 | -202.0 | -370.3 | -136.3 | -- | 1.6 | |
| 0.5 | 17.0 | 0.0 | 2,778.9 | -268,238.4 | 33.7 | 4.7 | 1.0 | |
| 0.9 | 3.9 | 0.0 | -3.3 | -- | -109.8 | -- | 1.2 |
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve... field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana. Address: 11611 North Meridian St, Carmel, IN, United States, 46032 Read more
President, CEO & Director
Mr. Brian Carrico
President, CEO & Director
Mr. Brian Carrico
Headquarters
Carmel, IN
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Neuraxis Inc (NRXS) stood at $ 5 Mln as on 31-Dec-24
The share price of Neuraxis Inc (NRXS) is $2.22 (NYSE) as of 15-May-2025 11:38 EDT. Neuraxis Inc (NRXS) has given a return of -21.28% in the last 1 years.
Neuraxis Inc (NRXS) has a market capitalisation of $ 17 Mln as on 14-May-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Neuraxis Inc (NRXS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Neuraxis Inc (NRXS) and enter the required number of quantities and click on buy to purchase the shares of Neuraxis Inc (NRXS).
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana. Address: 11611 North Meridian St, Carmel, IN, United States, 46032
The CEO & director of Mr. Brian Carrico. is Neuraxis Inc (NRXS), and CFO & Sr. VP is Mr. Brian Carrico.
There is no promoter pledging in Neuraxis Inc (NRXS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
22
|
|
|
20
|
|
|
18
|
|
|
2
|
|
|
0
|
|
|
0
|
|
|
0
|
|
|
0
|
|
|
1,172
|
| Neuraxis Inc. (NRXS) | Ratios |
|---|---|
|
Return on equity(%)
|
-2480.49
|
|
Operating margin(%)
|
-295.64
|
|
Net Margin(%)
|
-306.84
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Neuraxis Inc (NRXS) was $0 Mln.
$-0.05
(
